NeuroMab™ Anti-CD32b BBB Shuttle Antibody(NRZP-1022-ZP3177)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Immunogen

Recombinant soluble extracellular domain

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Applications

ELISA; WB; ADCC; Cyt; Block; In Vitro; In Vivo

Relevant Diseases

Systemic Lupus Erythematosus; Malaria

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

CD32b

Official Name

FCGR2B

Full Name

Fc fragment of IgG receptor IIb

Alternative Names

FCGR2B; CD32; CD32B; FCG2; FCGR2; IGFR2; Fc fragment of IgG receptor IIb; FcRII-c; FCGR2C

Product Pictures

ELISA

Figure 1 shows the binding of anti-CD32b antibodies to (Figure 1A) CD32bECDHis and (Figure 1B) CD32aECDHis measured by ELISA.

FCM

Figure 2 shows the binding of anti-CD32b antibodies to stably transfected IIA1.6 cells expressing full-length CD32b measured by flow cytometry.

ADCC

Figure 3 shows the ability of anti-CD32b antibody to induce Daudi cell lysis by ADCC compared to HuMab-KLH

FRET

Figure 4 shows CD32b TR-FRET based binding competition data. Maximum TR-FRET fluorescence was determined in samples without unlabeled mAb (which did not compete with labeled mAb). Background fluorescence was measured in samples without CD32bECDHis and CD32aECDHis. The inhibition of a-KLH-AlexaFluor 647 binding to CD32bECDHis and CD32aECDHis was represented by IC50 values (Table 6). The data for antibody 026 illustrate antibodies 020, 022, 024, 028, 053 and 063.

FuncS

Figure 5 shows the in vivo anti-tumor efficacy of anti-CD32b antibodies in a xenograft tumor model in SCID mice. Antibody was administered on day 0 (Figure 5A) or day 6 (Figure 5B) after tumor challenge; shown are mean counts per minute (cpm) values ± SEM for each treatment group.

FuncS

Figure 6 shows the in vivo anti-tumor efficacy of anti-CD32b antibodies in a xenograft tumor model in SCID mice. Antibody was administered on day 6 (Figure 6A and 6B) or 14 days after tumor challenge (Figure 6C); data shown are mean tumor burden ± SEM for each group.

FuncS

Figure 7 shows the ability of anti-CD32b antibodies to induce Daudi cell lysis by ADCC compared to HuMab-KLH. Data shown are mean ± SEM of triplicates.

FuncS

Figure 8 shows the binding of anti-CD32b antibodies to membrane-bound CD32b1 expressed on IIA1.6 cells. Data shown are mean MFI ± stdev of three independent experiments.